We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Molecular Diagnostic System Aims to Provide PCR Lab in the Palm of Your Hand for Diagnosing COVID-19 in 30 Minutes

By LabMedica International staff writers
Posted on 11 Nov 2021

A new molecular diagnostic system offers a significant advancement in rapid, precise and affordable diagnostic testing for the SARS-CoV-2 virus and is expected to provide results equivalent to lab-based PCR testing in less than 30 minutes. More...

Anavasi Diagnostics (Seattle, WA, USA) has been awarded USD 14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative to accelerate the launch and broad market availability of its AscencioDx molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2/COVID-19 virus. Previous NIH funding in August 2020 had allowed the Anavasi team to pivot from HIV to COVID-19 detection. The AscencioDx uses sophisticated LAMP (loop-mediated isothermal amplification) molecular diagnostic chemistry and hardware technology to detect HIV viral variants. Now, the same approach is poised to make COVID-19 testing easier and more accurate for everyone.

The AscencioDx offers rapid test results equivalent to lab-based PCR tests, easy and comfortable lower nasal swab sampling procedure, and positive test results in approximately 30 minutes. Its detector is reusable for at least 3,000 single-use COVID-19 tests and its price is comparable to less accurate antigen tests and much lower than lab-based PCR tests. While the initial application of the AscencioDx platform is for the detection of COVID-19, the technology is a perfect platform for the future of bacterial and viral testing.

Currently in clinical trials in the US, Anavasi expects to file its submission to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) in the near future. The initial EUA submission will claim effectiveness for administration by a licensed medical professional in a point-of-care setting, including physician offices, hospital emergency rooms, urgent care clinics, mobile testing sites, colleges and universities, as well as workspaces and other sites deemed appropriate by the healthcare professionals involved.

"At a time when Americans are seeking accurate testing options, our simple system promises to be the new gold standard," said Nelson Patterson, CEO of Anavasi Diagnostics. "It can provide results in approximately 30 minutes comparable to lab-based polymerase chain reaction (PCR) tests. In addition, the AscencioDx platform almost completely eliminates false positives and negatives so frontline health workers no longer need to order multiple tests to ensure an absolute diagnosis. It's a one and done process that's like having a PCR lab in the palm of your hand. We believe that fast, accurate and affordable testing will lead to faster treatment and better healthcare outcomes for patients. We want to save lives."

"The AscencioDx will set a new precedent in rapid affordable, simple-to-complete COVID-19 testing," said Patterson. "When our clinical testing is complete and our submission presented to the FDA, we expect results to demonstrate that no point-of-care test is more accurate. The novel combination of features will make this product unique in the marketplace."

"Future products are expected to include an all-in-one multiplex capability for testing various respiratory diseases at one time, which may ultimately provide impressive accuracy and flexibility, while also saving time and money," Patterson added.

Related Links:
Anavasi Diagnostics 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Ultra-Low Temperature Freezer
iUF118-GX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.